home / stock / nevpf / nevpf quote
Last: | $0.01 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.01 |
High: | $0 |
Low: | $0 |
Volume: | 210,000 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.01 | $0 | $0.01 | $0 | $0 | 210,000 | 05-21-2024 |
$0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 600 | 05-20-2024 |
$0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 204 | 03-04-2024 |
$0.02 | $0.02 | $0.02 | $0.02 | $0.02 | 7,000 | 01-05-2024 |
$0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 3,106 | 11-08-2023 |
$1e-06 | $1e-06 | $1e-06 | $1e-06 | $1e-06 | 2,000 | 04-04-2023 |
$0.01 | $0 | $0.01 | $0 | $0 | 61 | 10-12-2022 |
$0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 5,000 | 10-06-2022 |
$0.0217 | $0.0217 | $0.0217 | $0.0217 | $0.0217 | 5,000 | 08-30-2022 |
$0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 1,717 | 01-20-2022 |
$0.075 | $0.075 | $0.075 | $0.075 | $0.075 | 1,100 | 11-30-2021 |
$0.09 | $0.09 | $0.09 | $0.09 | $0.09 | 6,000 | 11-29-2021 |
$0.08 | $0.08 | $0.08 | $0.08 | $0.08 | 6,000 | 11-26-2021 |
$0.075 | $0.075 | $0.075 | $0.075 | $0.075 | 600 | 11-25-2021 |
$0.075 | $0.075 | $0.075 | $0.075 | $0.075 | 600 | 11-24-2021 |
$0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 400 | 11-23-2021 |
$0.065 | $0.065 | $0.065 | $0.065 | $0.065 | 2,000 | 11-22-2021 |
$0.075 | $0.075 | $0.075 | $0.075 | $0.075 | 200 | 11-19-2021 |
$0.075 | $0.075 | $0.075 | $0.075 | $0.075 | 110 | 11-18-2021 |
$0.07 | $0.08 | $0.07 | $0.08 | $0.07 | 5,130 | 11-17-2021 |
News, Short Squeeze, Breakout and More Instantly...
Neurovive Pharm Ab Ord Company Name:
NEVPF Stock Symbol:
OTCMKTS Market:
Neurovive Pharm Ab Ord Website:
- Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ...
LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM ...
Abliva AB (publ) (NEVPF) is expected to report for Q4 2023